吡虫啉、吡唑醚和莫昔丁联合用药的急性毒性和累积特性研究

O. Tochieva, M. Arisov
{"title":"吡虫啉、吡唑醚和莫昔丁联合用药的急性毒性和累积特性研究","authors":"O. Tochieva, M. Arisov","doi":"10.31016/1998-8435-2022-16-3-327-334","DOIUrl":null,"url":null,"abstract":"The purpose of the research is the study of acute oral and dermal toxicity, and cumulative properties of the combined drug based on imidacloprid, pyriproxyfen and moxidectin on mice and rats.Materials and methods. The studies were conducted as provided by the Guidelines of the State PharmacologicalCommittee, in the VNIIP – FSC VIEV vivarium in 2021. We studied the acute oral and dermal toxicity, as well as cumulative properties of the combined drug in the form of a solution for external use that contains imidacloprid, pyriproxyfen and moxidectin as active substances. Outbred male mice and male rats were used in studying toxicological characteristics of the drug. General methods were used in studying the acute oral toxicity in the mice and rats, acute dermal toxicity in the rats and cumulative properties of the prototype product in the mice.Results and discussion. The LD 50 of the prototype product was 800 mg/kg of the animal weight when administered orally to the mice, and 2520±916.7 mg/kg, to the rats. Subject to the established median lethal doses, the drug was classified as the 3rd hazard class according to the general hygienic classification (GOST 12.1.007-76). When studying the acute dermal toxicity in the rats, the LD50 of the drug exceeded the maximum possible dose of 10,000 mg/kg. According to the general hygienic classification (GOST 12.1.007-76), the drug was classified as the 4th hazard class. The accumulation factor was 8.25, in which case the drug can be classified as the group of substances with weak cumulative activity.","PeriodicalId":34353,"journal":{"name":"Rossiiskii parazitologicheskii zhurnal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study of the acute toxicity and cumulative properties of the combined drug based on imidacloprid, pyriproxyfen and moxidectin\",\"authors\":\"O. Tochieva, M. Arisov\",\"doi\":\"10.31016/1998-8435-2022-16-3-327-334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The purpose of the research is the study of acute oral and dermal toxicity, and cumulative properties of the combined drug based on imidacloprid, pyriproxyfen and moxidectin on mice and rats.Materials and methods. The studies were conducted as provided by the Guidelines of the State PharmacologicalCommittee, in the VNIIP – FSC VIEV vivarium in 2021. We studied the acute oral and dermal toxicity, as well as cumulative properties of the combined drug in the form of a solution for external use that contains imidacloprid, pyriproxyfen and moxidectin as active substances. Outbred male mice and male rats were used in studying toxicological characteristics of the drug. General methods were used in studying the acute oral toxicity in the mice and rats, acute dermal toxicity in the rats and cumulative properties of the prototype product in the mice.Results and discussion. The LD 50 of the prototype product was 800 mg/kg of the animal weight when administered orally to the mice, and 2520±916.7 mg/kg, to the rats. Subject to the established median lethal doses, the drug was classified as the 3rd hazard class according to the general hygienic classification (GOST 12.1.007-76). When studying the acute dermal toxicity in the rats, the LD50 of the drug exceeded the maximum possible dose of 10,000 mg/kg. According to the general hygienic classification (GOST 12.1.007-76), the drug was classified as the 4th hazard class. The accumulation factor was 8.25, in which case the drug can be classified as the group of substances with weak cumulative activity.\",\"PeriodicalId\":34353,\"journal\":{\"name\":\"Rossiiskii parazitologicheskii zhurnal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rossiiskii parazitologicheskii zhurnal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31016/1998-8435-2022-16-3-327-334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rossiiskii parazitologicheskii zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31016/1998-8435-2022-16-3-327-334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究的目的是研究吡虫啉、吡丙醚和莫西菌素复合药物对小鼠和大鼠的急性口服和皮肤毒性及累积特性。材料和方法。这些研究是根据国家药理学委员会的指南在2021年的VNIIP - FSC VIEV体内进行的。研究了该药物以吡虫啉、吡丙醚和莫西菌素为活性物质的外用溶液形式的急性口服和皮肤毒性以及累积特性。采用远交种雄性小鼠和雄性大鼠研究了该药物的毒理学特性。采用常规方法研究了小鼠和大鼠的急性口服毒性、大鼠的急性皮肤毒性以及样品在小鼠体内的累积性能。结果和讨论。小鼠口服原型产品的ld50为动物体重的800mg /kg,大鼠口服原型产品的ld50为2520±916.7 mg/kg。在确定中位致死剂量的前提下,按照一般卫生分类(GOST 12.1.007-76)将该药列为第三类危害。在大鼠急性皮肤毒性研究中,该药物的LD50超过了最大可能剂量10000 mg/kg。按照GOST 12.1.007-76的一般卫生分级标准,将该药列为第4类危险药品。积累因子为8.25,可归类为积累活性较弱的一类物质。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Study of the acute toxicity and cumulative properties of the combined drug based on imidacloprid, pyriproxyfen and moxidectin
The purpose of the research is the study of acute oral and dermal toxicity, and cumulative properties of the combined drug based on imidacloprid, pyriproxyfen and moxidectin on mice and rats.Materials and methods. The studies were conducted as provided by the Guidelines of the State PharmacologicalCommittee, in the VNIIP – FSC VIEV vivarium in 2021. We studied the acute oral and dermal toxicity, as well as cumulative properties of the combined drug in the form of a solution for external use that contains imidacloprid, pyriproxyfen and moxidectin as active substances. Outbred male mice and male rats were used in studying toxicological characteristics of the drug. General methods were used in studying the acute oral toxicity in the mice and rats, acute dermal toxicity in the rats and cumulative properties of the prototype product in the mice.Results and discussion. The LD 50 of the prototype product was 800 mg/kg of the animal weight when administered orally to the mice, and 2520±916.7 mg/kg, to the rats. Subject to the established median lethal doses, the drug was classified as the 3rd hazard class according to the general hygienic classification (GOST 12.1.007-76). When studying the acute dermal toxicity in the rats, the LD50 of the drug exceeded the maximum possible dose of 10,000 mg/kg. According to the general hygienic classification (GOST 12.1.007-76), the drug was classified as the 4th hazard class. The accumulation factor was 8.25, in which case the drug can be classified as the group of substances with weak cumulative activity.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
38
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信